These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 14629979)

  • 1. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
    Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
    J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product inhibition of the hepatitis C virus NS3 protease.
    Steinkühler C; Biasiol G; Brunetti M; Urbani A; Koch U; Cortese R; Pessi A; De Francesco R
    Biochemistry; 1998 Jun; 37(25):8899-905. PubMed ID: 9636031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies.
    Cicero DO; Barbato G; Koch U; Ingallinella P; Bianchi E; Nardi MC; Steinkühler C; Cortese R; Matassa V; De Francesco R; Pessi A; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):385-96. PubMed ID: 10366512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method.
    Li X; Zhang W; Qiao X; Xu X
    Bioorg Med Chem; 2007 Jan; 15(1):220-6. PubMed ID: 17064917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism.
    Barbato G; Cicero DO; Nardi MC; Steinkühler C; Cortese R; De Francesco R; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):371-84. PubMed ID: 10366511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function relationship of serine protease-protein inhibitor interaction.
    Otlewski J; Jaskólski M; Buczek O; Cierpicki T; Czapińska H; Krowarsch D; Smalas AO; Stachowiak D; Szpineta A; Dadlez M
    Acta Biochim Pol; 2001; 48(2):419-28. PubMed ID: 11732612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of selective eglin inhibitors of HCV NS3 proteinase.
    Martin F; Dimasi N; Volpari C; Perrera C; Di Marco S; Brunetti M; Steinkühler C; De Francesco R; Sollazzo M
    Biochemistry; 1998 Aug; 37(33):11459-68. PubMed ID: 9708981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.